Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an update on its pipeline and business.

Affimed Announces Pipeline and Business Update

Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger position. I provide a brief overview of the company's current partnerships and will discuss why I believe these partnerships are a vital component of a long thesis.

Affimed's Stockpile Of Partnerships Supports A Long-Term Investment

Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of a clinical data set on AFM13 at the 62nd American Society of Hematology Annual Meeting and Exposition. Dr. Ahmed Sawas, Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital, and principal investigator presented the updated results of a phase 1b/2a study in patients with CD30-expressing lymphoma with cutaneous involvement.

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma

 The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma, whereas in a separate study MSD's KEYTRUDA demonstrated an ORR of 69% and a CR of 22.4% as a monotherapy

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript

Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript

Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat the estimate of ($0.10).

Affimed: Q3 Earnings Insights

Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the three and nine months ended September 30, 2020 and provided an update on clinical and corporate progress.

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed's current pipeline

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets

 Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed's AFM13 and Cytokine-Activated Natural Killer Cells

 Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts highlighting data related to the company's lead innate cell engager (ICE®), AFM13, have been accepted for poster presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held  December 5-8, 2020.

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2020 results on Tuesday, November 10, 2020 and host a conference call at 8:30 a.m. ET to discuss financial results and corporate developments.

Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020

Heidelberg, Germany, and Santa Ana, California, October 20, 2020 – Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of the body's innate immune system, announced today that they entered into a clinical collaboration agreement to investigate the combination of AFM24, a CD16A/EGFR-targeted ICE®, with the autologous NK cell product SNK01. Pursuant to the collaboration, the companies plan to explore the combination in a first-in-human proof-of-concept (POC) trial in patients with EGFR-expressing tumors. The agreement follows a previous collaboration between the two companies in the preclinical setting to better understand the combined activity of their respective platforms. The results of the preclinical collaboration have shown substantive synergy between Affimed's ICE® molecules and NKMax America's autologous and cryopreserved allogeneic natural killer cell products.

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that preclinical data from its collaboration with The University of Texas MD Anderson Cancer Center and Washington University School of Medicine will be presented in an oral presentation at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held virtually on November 9-14, 2020.

Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the first patient was successfully dosed with allogeneic cord blood-derived natural killer (cbNK) cells preloaded with AFM13 and has moved on to the AFM13 monotherapy phase of the treatment cycle. This therapy was developed through a research collaboration with The University of Texas MD Anderson Cancer Center.

Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today announced that it has been awarded a grant supporting the further development of a unique approach for the discovery of functional antibodies using a microfluidic system. The grant was awarded from the Ministry of Industry and Trade of the Czech Republic as the managing authority Operational Program, Enterprise and Innovation for Competitiveness.

AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time.

Affimed to Present at Jefferies Virtual Cell Therapy Summit

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript

Shares of Affimed (NASDAQ:AFMD) moved higher by 4% in pre-market trading after the company reported Q2 results.

Affimed: Q2 Earnings Insights

Heidelberg, Germany, August 11, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the second quarter 2020 and provided an update on clinical and corporate progress.

Affimed Reports Second Quarter 2020 Financial Results and  Operational Progress

Heidelberg, Germany, August 5, 2020  – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointments of Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board.  Both these appointments were approved during the Annual General Meeting of Shareholders which took place on August 4, 2020.

Affimed Announces Two New Appointments to Its Supervisory Board

Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments.

Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Unlike a lot of companies that are focused on the adaptive immune system, Affimed is developing a novel suite of products aimed at boosting innate immunity to fight cancer.

News for Affimed Stock (AFMD)